10-Q quarterly report · filed Nov 5, 2026

LEMAITRE VASCULAR INC (LMAT) Q3 2026 10-Q Quarterly Report

Short answer

LEMAITRE VASCULAR INC (LMAT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $68M (up 11.3% year over year) with net income of $15M.

Q3 2026 key financials · XBRL

Revenue
$68M
+11.3% YoY · −3.4% QoQ
Net income
$15M
−13.5% YoY · −11.9% QoQ
Operating margin
26.0%
Gross margin
71.7%
EPS (diluted)
$0.65
−14.5% YoY · −12.2% QoQ

Source: XBRL data from the LEMAITRE VASCULAR INC (LMAT) Q3 2026 10-Q on SEC EDGAR. USD.

LEMAITRE VASCULAR INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $68.0M, up 11% YoY from $61.0M, driven by graft sales increasing $4.5M
  • Gross margin 71.7% vs 75.3% YoY, affected by 2025 ERC and $0.5M PhasTIPP excess charges
  • EMEA strongest geography, revenue up 18% to $20.8M; APAC weakest, up 5% to $4.4M
  • Cash $27.5M vs $28.2M at December 31, 2025; short-term securities increased to $362.2M
  • Operating cash flow $53.0M vs $58.1M YoY; dividends paid $17.1M and capital expenditures $7.4M

Risk Factors

  • Newly updated regulatory risk: FDA re-inspection of Artegraft facility identified additional observations in June 2026
  • Most material compliance risk: FDA may impose enforcement actions if corrective actions addressing the August 2025 warning letter prove unsatisfactory
  • Product liability risk: Recalls or defects could trigger significant costs, adverse publicity, and claims
  • Operational risk: Ongoing Artegraft remediation requires management resources and may affect operations or sales
  • Financial risk: Foreign currency exposure affected approximately 45% of sales outside the United States

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other LEMAITRE VASCULAR INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.